Zai Lab’s Post

Individualizing treatment strategies for patients with stage III non-small cell #lungcancer requires accurate clinical and pathological staging. Explore the evolving treatment journey for patients with NSCLC and earn free #CME here: https://bit.ly/3SWz1XK #MedEd #FOAMed #Oncology

Explore data from the latest abstracts covering urothelial and renal cell carcinoma with this Clinical Updates activity! Learn from UC and RCC expert Dr. Petros Grivas and earn free #CME: https://bit.ly/3N8cOCG #MedEd #FOAMed #Oncology

Around 6,500 clinical trials related to precision medicine in oncology have been registered in the past six years, indicating substantial research in this domain. https://lnkd.in/eme3VBKQ #oncology #precisionmedicine #clinicaltrials

Precision medicine is rapidly gaining prominence as a mainstream treatment approach in oncology. Join our latest webinar to understand this complex landscape of precision medicine therapies and discover the current trends and insights. Register now: https://bit.ly/4cEriEM #Oncology #PrecisionMedicine

For #ESMO2024, we have secured clinical experts across multiple tumor types who will review and discuss newly presented data and how they are likely to impact the current standards of care. Contact us to get the report details: https://lnkd.in/eUnmaV9q #CancerCare #Oncology #ImmunoOncology

The journey of a breast cancer patient is challenging enough without the added burden of CIPN, chemotherapy-induced peripheral neuropathy, a devastating side effect of taxane-based chemotherapies. Listen in as our CEO, Bob Linke, explains how Osmol's OSM-0205 aims to prevent nerve damage, allowing patients to continue their life-saving treatments without compromising their quality of life. Learn more at our lead candidate as we prepare to initiate clinical development later this year for OSM-0205: https://bit.ly/4c4jFHj #biopharma #oncology #clinicaltrials

Anti-PD1/PDL1 monotherapy has shown significant promise in improving overall survival (OS) for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), while also resulting in a lower incidence of treatment-related adverse events (TRAEs) compared to the standard of care (SOC), according to a study. View the complete article below ⤵️ #Oncology #Oncologist #InternalMedicine

🧪 "Tolerability and potential efficacy was observed with etigilimab (MPH313) and nivolumab (Opdivo) for patients with recurrent or advanced solid tumors and those with PD-L1 low disease" This year, a new clinical trial has proven that the combination of etigilimab and nivolumab improves tolerability and efficacy for patients with advanced solid tumors 👇 https://hubs.li/Q026pN3n0 #medicalimaging #oncology #clinicaltrials

Think-out-of-the-box: I was happy to make this talk during the TRANSLATE-IT CRCM last Symposium about the dark side of #ADCs (i.e. poor stability, not-that-large therapeutic window, limited distribution to solid tumors). Nevertheless, the #clinical #results are truly impressive and #cancers with once dismal prognoses such as #TNBC now have a brighter prognosis. However, the exact mechanisms underlying the efficacy of ADCs are likely to be far more complex than the simple "magic bullet" concept! #precisionmedicine #oncology

An #AI powered clinical decision support tool can significantly increase #cancer detection rates in primary care, according to study findings presented at the American Society of Clinical Oncology (ASCO) annual meeting. https://lnkd.in/d2dH4aqt #artificialintelligence #ASCO #clinicalresearch #medicalaffairs #oncology